ACUSPHERE PROCEEDS WITH AI-700 PHASE III TRIALS

A A

Acusphere has enrolled 700 patients in the pivotal Phase III clinical program for AI-700, its lead product candidate. AI-700 is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing, currently the leading procedure for detecting coronary heart disease.

The trial is designed to demonstrate that stress echo with AI-700 is comparable to nuclear stress testing in the detection of coronary heart disease. The number of patients estimated by the company to be required in this trial and achieve statistical significance is based on information derived from the company's prior trials.